Global Market Study on Triple-Negative Breast Cancer Treatment: Paclitaxel Drugs Segment to Hold More Than 50% Revenue Share Through 2026


Triple Negative Breast Cancer Treatment  Market
  • Published On : Sep-2018 |
  • Pages : 215 Pages |
  • Format :

This Persistence Market Research (PMR) report examines the ‘Global Triple-Negative Breast Cancer Treatment Market’ for the period 2018–2026. The primary objective of the report is to offer updates and information related to opportunities in the global triple-negative breast cancer treatment market.

The Triple-Negative Breast Cancer Treatment Market is Segmented Based on:

  • Drug Type
  • Distribution Channel
  • Region

This report covers the global triple-negative breast cancer treatment market performance in terms of revenue contribution from various segments. The report begins with an overview and definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the global triple-negative breast cancer treatment market along with a detailed opportunity analysis of the market. This is then followed by the key drivers, restraints and trends of the global triple-negative breast cancer treatment market.

The global triple-negative breast cancer treatment market is segmented based on drug type, distribution channel and regions. Based on drug type, the global triple-negative breast cancer treatment market is segmented into doxorubicin, cyclophosphamide, paclitaxel, docetaxel, carboplatin/cisplatin and others. Based on distribution channel, the global triple-negative breast cancer treatment market is segmented into hospital pharmacies and specialty cancer clinics. Geographically, the global triple-negative breast cancer treatment market is segmented into North America (the U.S. & Canada), Latin America (Brazil, Mexico, and Rest of Latin America), Europe (Germany, France, the U.K., Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, India, Australia, Japan, ASEAN and Rest of Asia Pacific) and Middle-East and Africa (GCC Countries, South Africa and Rest of MEA).

A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The forecast of the triple-negative breast cancer treatment market by country, drug type, and distribution channel is represented in a tabular form for each region. This section will help to understand the present scenario and opportunities of the triple-negative breast cancer treatment market in major countries by each segment.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key competitor firms in order to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to a market segment. The detailed profiles of players operating in the progressive multifocal leukoencephalopathy treatment market are also provided in the report, which highlight company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 2018–2026 and sets the forecast within the context of the triple-negative breast cancer treatment market by region. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections – by drug type and distribution channel – evaluate the historic market analysis and growth prospects of the triple-negative breast cancer treatment market for the period 2018–2026. We have considered 2017 as the base year and provided data for the forecast period.

The final section of the report represents the global scenario of the triple-negative breast cancer treatment market along with y-o-y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period as well as the absolute dollar opportunity for each year. This section will help to understand the overall growth of the triple-negative breast cancer treatment market and the opportunity analysis for every year over the forecast period.

To arrive at the market size, bottom-up approach is used to validate the total market size obtained for the triple-negative breast cancer treatment market. The forecast presented in the report provides total revenue of the triple-negative breast cancer treatment market over 2018–2026. PMR has used a triangulation methodology that is primarily based on experimental techniques, such as patient-level data to obtain precise market estimations for triple-negative breast cancer treatment market and insights on specific country/regions. The country-specific data is again analyzed to derive data at a regional level and then at the global level. This methodology ensures high quality and accuracy of information.

The factors considered while developing the estimates of the triple-negative breast cancer treatment market are disease epidemiology, treatment-seeking rate, ratio of population prescribed with different level of treatment for different stages of cancer.

The average selling price (US$) is derived by using weighted average pricing methodology.

On the other hand, PMR has also analyzed the triple-negative breast cancer treatment market by considering the revenue from the key players operating in a segment. The key players are segmented at the tier level with respect to their revenue, product portfolio and geographical presence. This process involves analysis of various annual reports of companies, investor presentations, SEC filings, 10k reports, earning call transcripts and press releases. This task is done to fetch substantial information about the key players, their respective revenues and estimate their respective market share.

Revenue growth of the key market players is analyzed over the historical period and qualitative assessment of new treatment pattern and use of combination therapy has been made in order to validate and align the resultant market numbers. The market structure is closely studied and analyzed at the regional level to map and ascertain incremental $ opportunity for companies, for instance, supply from domestic/regional players, small-scale enterprises or unorganized segments is also taken into consideration to arrive at the final market numbers.

While forecasting the size of the triple-negative breast cancer treatment market, we have considered the impact of several factors such as per capital healthcare expenditure, disposable income, drug approval and treatment pattern, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the triple-negative breast cancer treatment market and to identify the right growth opportunities in the global triple-negative breast cancer treatment market.

Triple-negative breast cancer is a type of cancer that does not have receptors for the hormones oestrogen and progesterone or the protein HER2. Triple-negative breast cancer is a rare type of cancer. About 10–20% of breast cancers are found to be triple negative. Triple-negative breast cancer does not responds to hormonal therapy or therapies that target HER2 receptors such as Herceptin (trastuzumab). The treatment combines surgery, radiotherapy and chemotherapy. Triple-negative breast cancer is more likely to spread beyond the breast and has chances of reoccurrence after 3 years. New chemotherapy drugs and combination drugs are under development for the treatment of triple-negative breast cancer.

Market Value and Forecast

The global triple-negative breast cancer treatment market is projected to grow at a CAGR of 4.7% throughout the forecast period (2018–2026).

Triple-Negative Breast Cancer Treatment Market: Key Insights

  • The global burden of breast cancer is increasing owing to growing aging population along with the changing life style and excessive consumption of tobacco and alcohol, which is consequently expected to drive the growth of the market for triple-negative breast cancer treatment over the forecast period.
  • Increasing research and development in the therapeutic areas such as cancer and adoption of new treatment types for breast cancer are further expected to spur the growth of the market for triple-negative breast cancer treatment in the near future
  • The robust pipeline of drugs in clinical development to treat breast cancers is also expected to drive the growth of the triple-negative breast cancer treatment market over the forecast period.
  • Collaborations among the key players in the research and development of new and innovative drug and therapies is also expected to drive the growth of the triple-negative breast cancer treatment market over the forecast period.
  • Many new treatments for the triple-negative breast cancer are under study among which are drug therapies. Introduction of new drugs and the treatment which further improve the diagnosis and treatment of triple-negative breast cancer are expected create lucrative growth opportunities for the new players entering the triple-negative breast cancer treatment
  • North America, followed by Europe, is expected to be the leading regional market for triple-negative breast cancer treatment, owing to growing prevalence of triple-negative breast cancer and increasing number of clinical trial for combination therapies.
  • Growing awareness regarding the treatment of triple-negative breast cancer in underdeveloped countries such as Africa is expected to drive the growth of the market for triple-negative breast cancer treatment over the forecast period.
  • Asia-Pacific triple-negative breast cancer treatment market is projected to have continuous growth over the forecast period due to increasing prevalence of breast cancer and improving treatment rate for cancer.
  • Improving treatment-seeking rate in middle- and low-income economies and access to safe and effective treatment and timely and accurate diagnosis of cancer is further expected to drive the growth of the triple-negative breast cancer market.
  • Growing emphasis on the research and development of drugs and therapies for rare disease creates a huge opportunity for the market of triple-negative breast cancer treatment.
  • Growing number of clinical trials for the combination therapies along with the collaboration among the major players is the key trend in the triple-negative breast cancer treatment market, which is projected to spur the growth of the triple-negative breast cancer treatment market over the forecast period.

triple negative breast cancer treatment market

Triple-Negative Breast Cancer Treatment Market: Regional Outlook

The global triple-negative breast cancer treatment market is segmented into five key regions, namely North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. In terms of value, North America is expected to be the leading regional market for triple-negative breast cancer treatment and is expected to have significant growth during the forecast period. The Asia Pacific excluding China triple-negative breast cancer treatment market is projected exhibit significant growth over the forecast period due to increasing prevalence of triple-negative breast cancer and rising diagnosis and treatment rate in the region, particularly in China and India.

Triple-Negative Breast Cancer Treatment Market: Key Players

Examples of some of the key players operating in the global triple-negative breast cancer treatment market are AstraZeneca PLC, Pfizer, Inc. , F. Hoffman - La Roche Ltd. , Bristol-Myers Squibb Company, Novartis AG, Mylan N.V. , Eli Lilly and Company, Celgene Corporation, Sanofi S.A., and Johnson & Johnson Services, Inc., among others.

Company Profiles

  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • F. Hoffman - La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Mylan N.V.
  • Eli Lilly and Company
  • Celgene Corporation
  • Sanofi S.A.
  • Others.
Back To Top